Clofarabine

Generic Name
Clofarabine
Brand Names
Clolar, Evoltra
Drug Type
Small Molecule
Chemical Formula
C10H11ClFN5O3
CAS Number
123318-82-1
Unique Ingredient Identifier
762RDY0Y2H
Background

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...

Indication

For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.

Associated Conditions
Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
Associated Therapies
-
Clinical Trials
Related News

S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2
Completed
Conditions
Leukemia
Interventions
Drug: clofarabine
Drug: cytarabine
First Posted Date
2006-06-15
Last Posted Date
2015-03-25
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
36
Registration Number
NCT00337168
Locations
🇺🇸

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

CCOP - Montana Cancer Consortium, Billings, Montana, United States

🇺🇸

Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States

and more 88 locations

A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

First Posted Date
2006-04-19
Last Posted Date
2014-04-14
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
50
Registration Number
NCT00315705
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 10 locations

Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

First Posted Date
2006-03-06
Last Posted Date
2015-11-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
65
Registration Number
NCT00299156
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
Leukemia
First Posted Date
2006-02-24
Last Posted Date
2018-08-10
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
53
Registration Number
NCT00295841
Locations
🇺🇸

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders

First Posted Date
2006-02-17
Last Posted Date
2010-05-06
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
70
Registration Number
NCT00293410
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Clofarabine
First Posted Date
2005-10-18
Last Posted Date
2013-08-13
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
8
Registration Number
NCT00241371
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Non-Hodgkin's Lymphoma
Interventions
Drug: Clofarabine
First Posted Date
2005-09-20
Last Posted Date
2017-12-06
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
6
Registration Number
NCT00201669
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Phase 1
Completed
Conditions
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Interventions
Drug: CLOFARABINE
First Posted Date
2005-09-12
Last Posted Date
2017-11-29
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
33
Registration Number
NCT00156013
Locations
🇺🇸

Oncology Specialists, SC, Park Ridge, Illinois, United States

Investigation of Clofarabine in Acute Leukemias

First Posted Date
2004-12-03
Last Posted Date
2015-03-25
Lead Sponsor
University of Texas
Target Recruit Count
64
Registration Number
NCT00098033

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

First Posted Date
2004-07-23
Last Posted Date
2012-08-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
95
Registration Number
NCT00088218
Locations
🇺🇸

M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy